Revenue Comparison
Chart: Revenue Comparison. Values in USD billions. In Q2 2026: Sanofi 13.284, CSL 3.6525.
* CSL reports semi-annually. Values are evenly split across both quarters within each half.
Sanofi vs CSL Net Worth and Market Cap
Sanofi (SNY) and CSL (CSL.AX) are peers in Vaccines. Sanofi reported revenue of $13.3B as of Q2 2026, compared with $7.3B for CSL. Sanofi leads on revenue.
Sanofi's gross margin is 75.5% versus 44.4% for CSL. Sanofi's net margin is 2.8% versus -40.2% for CSL.
Key differences
- Revenue growth from Q2 2025 to Q2 2026: Sanofi +14.6%, CSL +0.7%.
- Sanofi's KPIs on Sterling include Beyfortus Net Sales (Quarterly) and Dupixent Net Sales by Region (Quarterly).
- CSL's KPIs on Sterling include Behring Revenue by Therapy (Annual) and Behring IVIG vs SCIG Revenue (Annual).
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Sanofi, CSL.| Metric | Sanofi | CSL |
|---|---|---|
| Market Cap | - | - |
| Revenue | $13.28B | $7.30B |
| Cost of Revenue | $3.26B | $4.06B |
| Gross Profit | $10.03B | $3.24B |
| Operating Income | $2.58B | $1.39B |
| Net Income | $370.00M | $-2.94B |
| R&D Expense | $2.41B | $614.00M |
| Earnings Per Share | $0.15 | -$6.14 |
| Gross Margin | 75.5% | 44.4% |
| Operating Margin | 19.4% | 19.0% |
| Net Profit Margin | 2.8% | -40.2% |
| Free Cash Flow | $4.22B | $1.76B |
| Cumulative Free Cash Flow | $51.81B | $21.56B |
| Operating Cash Flow | $5.85B | $2.09B |
| Cash & Equivalents | $6.86B | $1.51B |